Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05654181 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05654181 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 20 participants.
The verdict
NCT05654181, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is the first clinical study with PF-07328948. The safety, tolerability, and plasma pharmacokinetics and pharmacodynamics of PF-07328948 after administration of escalating, single, oral doses will be evaluated.
Interventions
- DRUG Placebo
- DRUG PF-07328948
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-10-17 |
| Est. Completion | 2023-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05654181
The ClinicalTrials.gov registry entry for NCT05654181 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05654181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05654181 about?
NCT05654181 is a clinical study titled "A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants". This study is the first clinical study with PF-07328948. The safety, tolerability, and plasma pharmacokinetics and pharmacodynamics of PF-07328948 after administration of escalating, single, oral doses will be evaluated.
What is the current status of trial NCT05654181?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-10-17. Estimated completion is 2023-05-03.
What interventions are being tested in trial NCT05654181?
The interventions under investigation include: Placebo (DRUG), PF-07328948 (DRUG).
Who is sponsoring clinical trial NCT05654181?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.